menu ☰
menu ˟

FDA grants orphan drug status to BGB324 for AML

19 Nov 2014
The FDA granted orphan drug designation to BGB324 for the treatment of patients with acute myeloid leukemia, its manufacturer announced recently.Based on preclinical research, BGB324 (BerGenBio) — a selective inhibitor of Axl receptor tyrosine kina...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.